acquisition

Emera’s shares hit an all-time high just before the onset of the COVID-19 pandemic and the stock market downturn in March 2020. We feel the stock will regain that peak and move even higher.

That’s partly because the power generator is replacing its coal-fired plants with cleaner-burning natural gas, hydro power and solar....

CALIAN GROUP, $58.00, is a buy. The Ottawa-based company (Toronto symbol CGY; TSINetwork Rating: Extra Risk) (www.calian.com; Shares o/s: 9.8 million; Market cap: $588.8 million; Dividend yield: 1.9%) is now buying InterTronic Solutions Inc....

Intact Financial dropped along with the market when COVID-19 first hit—the stock fell to as low as $104.81 in March 2020. But the shares have rebounded 39%, close to all-time highs, as investors again appreciate Intact’s underlying business strength. Meantime, we think this Power Buy is poised to keep moving even higher.


INTACT FINANCIAL, $145.60, is a buy. The insurer (Toronto symbol IFC; TSINetwork Rating: Extra Risk) (www.intactfc.com; Shares outstanding: 143.0 million; Market cap: $25.9 billion; Dividend yield: 2.3%) is Canada’s largest provider of property and casualty coverage: it insures more than five million individuals and businesses....

There’s little doubt that the developing world’s aging population will help drive up global spending on medical services in the years to come. Medical device makers, however, are also well positioned to capture a share of that increased spending.


We continue to see attractive investment opportunities for our subscribers among the top device manufacturers—and that includes Boston Scientific. We recommend this stock as a Power Buy.


BOSTON SCIENTIFIC CORP., $37.50, is a buy. The company (New York symbol BSX; TSINetwork Rating: Average) (www.bostonscientific.com; Shares outstanding: 1.4 billion; Market cap: $54.3 billion; No dividends paid) develops and markets medical devices used in minimally invasive procedures....

A: Veeva Systems Inc., $317.63, symbol VEEV on New York (Shares outstanding: 136.4 million; Market cap: $48.2 billion; www.veeva.com), is a provider of Internet-based customer relationship management (CRM) software for the life sciences, cosmetics and consumer-products industries.


The San Francisco-based company has more than 861 customers, ranging from large pharmaceutical firms to biotech startups.

In September 2018, Veeva launched Veeva Vault Clinical Data Management System (CDMS)—a cloud application to help life sciences companies better manage their clinical data....

Continuing COVID-19 lockdowns, particularly in Ontario and Quebec, will undoubtedly limit sales and earnings for these leading retailers. However, all of them have expanded their online businesses in the past few years. That should help them handle any longer-term shift away from in-store shopping.


We feel all four are poised to move higher in 2021 as the economy re-opens....

CN’s shares have shot up nearly 50% from their March 2020 low of $92. Investors should expect the company to continue benefiting as the economy recovers from the COVID-19 pandemic. The recent cancellation of the Keystone XL oil pipeline by new U.S. president Joe Biden should also push more crude oil onto its rail networks.


Meantime, the company continues to improve the efficiency of its rail networks....

NEWMONT CORP., $58.91, remains a buy. The company (New York symbol NEM; Shares outstanding: 803.4 million; Market cap: $47.9 billion; TSINetwork Rating: Average; Dividend yield: 2.7%; www.newmont.com) now plans to repurchase up to $1.0 billion of its common shares over the next 18 months....

We have singled out two stocks and one ETF as your #1 buys for 2021. Each offers investors long-term growth prospects at a reasonable price. Meanwhile, all three are in a strong position to weather the current wave of COVID-19. Moreover, each is poised for solid gains as new vaccines help kick-start global economic growth.


ENBRIDGE $44.66 is a #1 Buy for 2021. The firm (Toronto symbol ENB; Shares outstanding: 2.0 billion; Market cap: $89.4 billion; TSINetwork Rating: Above Average; Dividend yield: 7.5%; www.enbridge.com) operates pipelines that pump Western Canadian oil and gas to eastern Canada and the U.S....

Alimentation Couche-Tard has rewarded our subscribers with big gains over the years. We first recommended it in our December 2008 issue at $15.50 a share. Since then, the stock has split 3-for-1 and then 2-for-1. That takes our cost down to $2.58 a share—and gives you a tremendous 1,447.7% gain!

Meanwhile, the company’s outlook remains positive, and we think the shares can go a lot higher....